Biogen (HAM:IDP) Pretax Margin %

: 17.80% (As of Mar. 2023)

View and export this data going back to 2001. Start your Free Trial

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Biogen's Pre-Tax Income for the three months ended in Mar. 2023 was €409 Mil. Biogen's Revenue for the three months ended in Mar. 2023 was €2,300 Mil. Therefore, Biogen's pretax margin for the quarter that ended in Mar. 2023 was 17.80%.

The historical rank and industry rank for Biogen's Pretax Margin % or its related term are showing as below:

HAM:IDP' s Pretax Margin % Range Over the Past 10 Years
Min: 15.89 Med: 41.23 Max: 49.56
Current: 36.45

HAM:IDP's Pretax Margin % is ranked better than
96.17% of 1044 companies
in the Drug Manufacturers industry
Industry Median: 3.60 vs HAM:IDP: 36.45

Biogen Pretax Margin % Historical Data

The historical data trend for Biogen's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Pretax Margin %

43.85

49.56

37.54

15.89

35.31

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Pretax Margin %																13.72	49.03	54.66	23.73	17.80

Biogen Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Biogen's Pretax Margin for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	3390.659	/	9603.69
	=	35.31 %

Biogen's Pretax Margin for the quarter that ended in Mar. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Mar. 2023 )	/	Revenue (Q: Mar. 2023 )
	=	409.372	/	2300.442
	=	17.80 %

Biogen (HAM:IDP) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Biogen Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Biogen's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (HAM:IDP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (HAM:IDP) Headlines

No Headlines